Who is this protocol a good fit for?

Anyone considering BPC-157 who wants the honest evidence before discussing it with a clinician. Athletes checking WADA and anti-doping status. Readers who have seen “Wolverine stack” claims and want the actual trial evidence. Readers comparing BPC-157 to FDA-approved peptides like semaglutide or tesamorelin

What are the cautions for this protocol?

Not FDA-approved for any human use; sold as an unregulated research chemical with no purity or sterility guarantee.. Banned at all times under WADA's anti-doping code (S0 and S2); can result in a competition ban if detected.. Human safety and efficacy data is essentially absent; one relevant trial is recruiting, not reporting results.. Educational only, not medical advice.

← Home / Peptides / YourProtocol / BPC-157: Evidence, Legal Status, and Safety

Peptides Peptides

BPC-157: Evidence, Legal Status, and Safety

BPC-157 is the most popular “research peptide” on the market, but the human evidence does not match the hype. Almost all of the evidence is animal and preclinical; the only human trial in progress (a hamstring-strain study) is still recruiting, not reporting results. It is not FDA-approved for any human use, sold as an unregulated research chemical, and banned at all times under WADA's anti-doping rules.

🧪

YourProtocol

YourProtocol Research

In-house · Synthesized from the cited primary sources

Daily time

5 min

Difficulty

Beginner

Sources

What the evidence says

What it is

Understand what's actually being sold

A synthetic fragment derived from a peptide first isolated from human gastric juice, promoted for tendon, ligament, gut, and wound healing, often marketed as a “Wolverine stack” alongside TB-500.

The marketing framing (“Wolverine stack”) is a branding term from self-experimenters, not a clinical designation.

Research synthesis of BPC-157 evidence, 2025-2026

For this step

No product needed

Evidence tier: C

See what the human evidence actually is

Almost all evidence is animal and preclinical. One human trial is currently recruiting (ClinicalTrials.gov NCT07437547, acute hamstring strain) but has not reported results. No completed, published human RCT with efficacy outcomes was independently verified.

Popularity and an in-progress trial do not raise a peptide's evidence tier; this stays Tier C until a completed human RCT reports a result.

2025 systematic review, orthopaedic sports medicine; ClinicalTrials.gov NCT07437547

For this step

No product needed

Legal status

Know where it actually stands

Not FDA-approved for any human use; sold almost exclusively as an unregulated “research chemical, not for human consumption.” A reported removal from the FDA's restricted-compounding list (around April 2026) is unconfirmed pending a formal review in July 2026. Banned at all times under WADA's code (S0 and S2 categories).

“Legal to buy as a research chemical” is not the same thing as “approved as a medical product,” and a substance can be both gray-market to purchase and career-ending to test positive for.

USADA; FDA 503A Category 2 reporting (unconfirmed)

For this step

No product needed

Safety

Know the real risk

No FDA safety review exists for human use. The FDA's own restricted-compounding flag raised concerns about potential immune reactions, unknown long-term safety, and impurity risk from unregulated manufacturing. Because BPC-157's proposed mechanism involves promoting tissue growth and blood-vessel formation, there is a theoretical, unproven concern about tumor-growth-promoting effects that Andrew Huberman has specifically flagged. Gray-market vials carry no quality-control guarantee.

A mechanism that promotes tissue growth cuts both ways: it's the proposed benefit and the proposed risk.

FDA Category 2 flag; Huberman Lab peptide-therapeutics episode

For this step

No product needed

What it is

BPC-157 is a synthetic, “stable” fragment derived from a peptide originally isolated from human gastric juice. It is promoted heavily for injury healing, gut repair, and tendon or ligament recovery. This page reports the honest evidence tier, legal status, and safety picture; it does not describe how to use it.

Why it works▼

The evidence base is overwhelmingly animal and preclinical: a 2025 systematic review of BPC-157 in orthopaedic sports medicine and a 2023 literature and patent review are both explicit that human clinical evidence is sparse. A genuine, currently-recruiting human trial exists, NCT07437547, testing subcutaneous BPC-157 against placebo for acute hamstring muscle strain, but it is in progress, not completed proof. Older references to human inflammatory bowel disease trials appear inside some preclinical papers, but an independently verifiable, completed, peer-reviewed human RCT report with efficacy outcomes could not be confirmed, so that specific claim is not made here. The FDA had flagged BPC-157 on its 503A Category 2 restricted-compounding list in late 2023 over safety-data gaps; multiple peptide-industry sources report it was removed from that list around April 22, 2026, pending a Pharmacy Compounding Advisory Committee review scheduled for July 23 to 24, 2026. That removal has not been independently confirmed directly against FDA.gov, so it should be treated as unconfirmed, not settled. USADA lists BPC-157 as prohibited under WADA's code at all times, in both the non-approved-substances (S0) and peptide-hormone (S2) categories. Peter Attia has publicly named BPC-157 as his “weakest evidence bucket” among the peptides he discusses, citing uncertain origins and animal data that does not replicate in human studies. Andrew Huberman has described “vast amounts of animal data” but only one poor-quality human study, and flags a real, mechanism-based safety concern: BPC-157's proposed angiogenesis-promoting effect could theoretically accelerate hidden tumor growth.

The evidence

Sources 5

Primary sources behind this page, cited straight to the source: peer-reviewed papers and reporting. Select any to view it here.

BPC-157 for Acute Hamstring Muscle Strain Repair (ClinicalTrials.gov NCT07437547, currently recruiting)

Paper

Emerging Use of BPC-157 in Orthopaedic Sports Medicine (systematic review, 2025)

Paper · SAGE Journals

USADA: BPC-157, a Prohibited Peptide

Article · usada.org

Peter Attia, AMA #83: Peptides, evaluating the science, safety, and hype (BPC-157 named his “weakest evidence bucket”)

Article · peterattiamd.com

Huberman Lab: Benefits & Risks of Peptide Therapeutics for Physical & Mental Health (BPC-157 segment)

Article · hubermanlab.com

Source viewer

Loading the first source…

Is this for you?

Good fit if

Anyone considering BPC-157 who wants the honest evidence before discussing it with a clinician
Athletes checking WADA and anti-doping status
Readers who have seen “Wolverine stack” claims and want the actual trial evidence
Readers comparing BPC-157 to FDA-approved peptides like semaglutide or tesamorelin

Cautions

Not FDA-approved for any human use; sold as an unregulated research chemical with no purity or sterility guarantee.
Banned at all times under WADA's anti-doping code (S0 and S2); can result in a competition ban if detected.
Human safety and efficacy data is essentially absent; one relevant trial is recruiting, not reporting results.
Educational only, not medical advice.

Common questions

Is BPC-157 safe?▾

We do not know, and that is the honest answer. There is essentially no completed human clinical trial data on BPC-157's safety. One human trial for a sports injury is currently recruiting (ClinicalTrials.gov NCT07437547) but has not reported results. The FDA has flagged it as a substance with insufficient safety data for compounding, and because it is sold as an unregulated research chemical, purity and actual dosage are not guaranteed by any authority.

Has BPC-157 actually been tested in humans?▾

Almost all of the evidence is animal and preclinical. A currently-recruiting human trial exists for acute hamstring strain (NCT07437547), but it has not reported results, so there is no completed human RCT proving efficacy yet.

Is BPC-157 legal?▾

It is not FDA-approved for any human use and is sold as an unregulated research chemical, a legal gray area, not an approved medical product. It is also banned at all times for competitive athletes under WADA's code.

What do credible experts actually say about BPC-157?▾

Peter Attia has called it his “weakest evidence bucket” among the peptides he discusses. Andrew Huberman describes vast animal data but only one poor-quality human study, and flags a mechanism-based theoretical concern about tumor growth.

Get the next protocol first

New expert protocols and evidence updates, cited to the source. No spam; unsubscribe anytime.

Not medical advice. This page is for education only and is not a substitute for professional medical care. Consult a qualified clinician before changing your health routine.
Editorial disclosure. This protocol is written and fact-checked by the YourProtocol editorial team directly from the primary sources cited below; it is not written or reviewed by any outside expert.

BPC-157: Evidence, Legal Status, and Safety

Read the evidence

Read it